Compare Amylx Pharmaceuticals Inc (AMLX) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Vanguard Real Estate Index Fund ETF trades at $97.2. Which is the better fit depends on your goals.
| AMLX | VNQ | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | — |
52-Week High | $18.70 | $98.66 |
52-Week Low | $7.64 | $87.00 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
VNQ trades at $97.32, up 0.24% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 56.24, while recent news highlights REIT sector resilience amid interest rate pressures. Support levels cluster around $96-97 with resistance at $98.
The REIT ETF faces headwinds from elevated interest rates but benefits from steady dividend income and sector recovery signs. Key risks include Fed policy uncertainty and inflation persistence, while institutional sentiment remains cautiously optimistic about real estate fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
